Rigosertib
Rigosertib (ON-01910) is a potent, non-ATP-competitive PLK1 inhibitor (IC50: 9 nM) and multi-kinase inhibitor that induces apoptosis via PI3K/Akt pathway inhibition, promotes histone H2AX phosphorylation, and causes G2/M cell cycle arrest. It has demonstrated anti-tumor activity in both in vitro and in vivo cancer research models, including studies in myelodysplastic syndromes.
Product Specifications
CAS Number
592542-59-1
Product Name Alternative
Cdk1, Apoptosis, BCR-ABL, BcrAbl, Inhibitor, Flt1, Fyn, ON01910, ON-01910, ON 01910, PLK1, PLK, PLK2, inhibit, Src, Rigosertib, Polo-like Kinase (PLK), PDGFR, Phosphoinositide 3-kinase, PI3K
Field of Research
Cardiovascular Research, Cell Biology, Signal Transduction
Purity
97.33% (May vary between batches)
Solubility
DMSO:75 mg/mL (166.12 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.43 mM)
Smiles
C (=C/S (CC1=CC (NCC (O) =O) =C (OC) C=C1) (=O) =O) \C2=C (OC) C=C (OC) C=C2OC
Molecular Formula
C21H25NO8S
Molecular Weight
451.49
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
